1. Home
  2. Companies
  3. ENP
  4. Material Events

Entropy Neurodynamics (ASX:ENP) — Material Events

ASX:ENP · 17 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 1 article Significant 14 articles Notable 2 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
14
Entropy Neurodynamics Posts 50% Remission in BED Trial and Expands IBS Patent PortfolioMedium
Entropy Neurodynamics reports strong Phase 2 clinical results in BED and IBS, advances TRP-8803 development and IP portfolio
22 July 2026 ·Quarterly Activities Report & Appendix 4C ·85
Entropy Neurodynamics Advances World-First Psilocin Trial for Binge Eating DisorderMedium
Entropy Neurodynamics advances TRP-8803 clinical trial for BED, raises $6.1M, and rebrands
30 Jan 2026 ·Quarterly Activities Report ·85
Entropy Neurodynamics Advances IV Psilocin Therapy with 50% BED Remission and Expanded TrialsHigh
Entropy Neurodynamics reports improved FY26 results and promising clinical progress with TRP-8803 in Binge Eating Disorder
28 Aug 2026 ·Annual Report and Financial Results ·85
Entropy Neurodynamics Files New US Patent to Strengthen TRP-8803 IBS Therapy IPMedium
Entropy Neurodynamics files new US patent to advance TRP-8803 IBS therapy following strong Phase 2a results
5 May 2026 ·Patent Filing Announcement ·85
Entropy Neurodynamics Secures Patent to Protect TRP-8803’s Precision IV Psychedelic TherapyMedium
Entropy Neurodynamics secures Australian patent for TRP-8803 IV dosing method, strengthening IP through 2042
12 Feb 2026 ·Patent Grant Announcement ·85
Entropy Neurodynamics Validates Psychedelic Therapy with 80% Drop in Binge EatingMedium
Entropy Neurodynamics reports 80% sustained reduction in binge eating from Phase 2a trial of oral psilocybin, validating lead IV psilocin asset
13 Jan 2026 ·Clinical Trial Results Announcement ·85
Entropy Neurodynamics Advances Controlled Psychedelic Therapy in Binge Eating Disorder TrialMedium
Entropy Neurodynamics doses third patient in TRP-8803 BED trial achieving controlled psychedelic response
14 Apr 2026 ·Clinical Trial Update ·85
Entropy Neurodynamics Advances Psychedelic Therapy with $6.1M Raise and Clinical MilestonesMedium
Entropy Neurodynamics reports reduced half-year loss, advances TRP-8803 clinical trial, raises $6.1M
27 Feb 2026 ·Appendix 4D Half-year report ·85
Entropy’s TRP-8803 Shows Early Promise in Treating Binge Eating DisorderMedium
Entropy Neurodynamics Reports Promising Early Clinical Results for TRP-8803 in Binge Eating Disorder
22 Jan 2026 ·Clinical Trial Update ·85
Entropy Neurodynamics Doses First Patient in Groundbreaking IV Psilocin BED TrialMedium
Entropy Neurodynamics doses first patient in pioneering IV psilocin BED trial
2 Dec 2025 ·Clinical Trial Update ·85
Entropy Neurodynamics Reports Promising Early Results in TRP-8803 BED Trial and Secures Patent ProtectionMedium
Entropy Neurodynamics advances TRP-8803 clinical trial with positive early results and secures patent protection
28 Apr 2026 ·Quarterly Activities Report ·85
Entropy Neurodynamics Secures South African Patent for Psilocybin Fibromyalgia TherapyMedium
Entropy Neurodynamics granted South African patent for psilocybin fibromyalgia treatment
20 July 2026 ·Patent Grant Announcement ·75
Entropy Neurodynamics Secures GMP Manufacturing for TRP-8803 Psilocin TherapyMedium
Entropy Neurodynamics partners with BioCina for GMP manufacturing of TRP-8803 psilocin formulation
19 Aug 2026 ·Manufacturing Agreement Announcement ·75
Entropy Neurodynamics Advances Psychedelic Therapy with First Patient Dosing CompleteMedium
Entropy Neurodynamics completes first patient dosing in TRP-8803 Binge Eating Disorder trial
16 Dec 2025 ·Clinical Trial Update ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.